ÂÜÀòÂÒÂ×

Mark is Chief Scientific Officer and co-founder of Relay Therapeutics, senior lecturer in the Department of Biological Engineering at MIT, and advisor and consultant for Schrödinger. He has directly contributed to seven marketed drugs and several others currently in mid-stage clinical trials. Previously, Mark was chief technology officer and chair of the scientific advisory board of Vertex Pharmaceuticals. Mark is a co-inventor of the hepatitis c virus (HCV) protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), both for the treatment of HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor). He is also a co-inventor of eight other clinical candidates in the areas of cancer, inflammation/immunology, and infectious disease, and was responsible for starting many of Vertex’s programs in these and other disease areas. Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against infection and cardiovascular and ocular diseases including dorzolamide, which was commercialized in two products, Trusopt® and the combination medicine Cosopt® (dorzolamide/timolol). Trusopt was the first marketed drug in pharmaceutical history to result from a structure-based drug design program. Mark is a member of numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations. He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles. Mark holds a Ph.D. in Organic Chemistry from Yale University and a BS, summa cum laude, in Chemistry and Applied Mathematics from Fairfield University.